Current frontline treatment for common nodal PTCL. Treatment of patients with nodal PTCL eligible for curative therapy. In the absence of a clinical trial, patients with ALCL and CD30-positive PTCLs receive induction therapy with BV-CHP. Patients with CD30-negative PTCL receive CHOEP (if eligible for intensive therapy) or CHOP. We offer consolidation with ASCT in the first CR for fit patients with higher-risk ALK-positive ALCL (International Prognostic Score of ≥2) and those with other common nodal PTCL entities.